Edwards Lifesciences (NYSE:EW) saw a 7% increase in after-hours trading following Q2 results, which exceeded expectations for both profit and revenue.
The company has also raised its outlook for the year ahead.
In the latest quarterly report, Edwards Lifesciences announced a revenue of $1.53B, marking an 11.7% increase compared to the same period last year. This figure surpassed analysts' estimates by $40M.
Additionally, the adjusted profit was reported at $0.67 per share, which also exceeded consensus expectations.
The company has updated its sales growth guidance for 2025, now projecting an increase of 9-10%, up from the previous estimate of 8-10%. For TAVR sales, the guidance has been raised to 6-7% from 5-7%.
The company reiterated its 2025 guidance for TMTT and surgical sales while also increasing its adjusted EPS guidance to a range of $2.40 to $2.50 at the high end.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.